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Summary: Because of the high market growth of biologics drugs- temperature sensitive 
pharmaceutical products, the cold chain management has become an increasingly 
important component of the overall pharmaceutical supply chain. On the other hand, the 
emerging economics have been the main driving force of global pharmaceutical market, 
especially China, with nearly 20% CAGR in pharmaceutical market in the past 5 years, is 
the most promising region and could be the second largest pharmaceutical market in the 
world by 2020. To explore the opportunities in cold chain management in emerging 
economics, this research chooses China as a case for study. As a pioneer study,  this 
research is to analyze the market trend and policy effects on pharmaceutical cold chain in 
China, to map the key supply chain issues on cold chain management, and to point out 
opportunities in the near future.  
Yen Chen holds a Master of Science, Biophotonics Engineering 
from National Yang-Ming University, Taiwan. While a Manager 
at Industrial Technology Research Institute, Yen Chen led a team 
to conduct a range of strategy planning and market analysis 
projects in healthcare industry.  Following his education that 
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work in a bio venture capital/ fund as a Senior Assistant Vise 
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Pharmaceutical Cold Chain in Emerging Economics 
- The Case of China 
KEY INSIGHTS 
1. 3PL could be a new business opportunity in China’s pharmaceutical cold
chain in long-term. The current cold chain logistic is mostly self-build by big
pharmaceutical companies. However, once the new regulation completely
implemented in the near future and also the industry standards are
practiced well, 3PL could be a solution to the industry.
2. From now to 2016, new technology and equipment will be highly in need to
build a modern pharmaceutical cold chain system in China.
3. To design a successful new business model in China’s pharmaceutical cold
chain, the model should highly align with the new regulations and the new
China’s national healthcare reforms.
The global and emerging 
pharmaceutical market  
Driven by scientific and technological 
advances, coupled with increasing demand 
for medicines from aging population, the 
economics growth of emerging countries 
and trade liberalization, global 
pharmaceutical market is growing steadily, 
with sales reaching $1.08 trillion in 2011–a 
year-on-year increase of 7.8%, and could 
be worth nearly $1.6 trillion by 2020. 
 
 
Figure 1: China is the most promising emerging 
market by 2020  
Source: PwC (2012) 
Emerging courtiers will be the main 
market driving force, not only because the 
natural demand are rising but also the 
governments of the growth economies are 
improving access to healthcare, such as 
Brazil’s introducing mobile clinics for 
rural communities, China’s on track with a 
US$200 billion programme to extend 
health insurance cover to 100% of the 
population and India’s National Rural 
Health Mission. Basically, BRIC will still 
be the first tier emerging market and show 
very strong growing power; especially 
China is expected to be the world’s second 
largest pharmaceutical market after the US 
in 2016, with high growth rate and sales 
quantity. (See Figure 2) 
 
 
Figure 2: China is the most promising emerging 
market by 2020 
Source: PwC (2012) 
In term of pharmaceutical supply chain, 
not only the new business model will drive 
it uprated but also the integration of 
pharmaceuticals, healthcare, and medical 
device industry to end user will restructure 
the supply chain system. That is, more 
innovations and various emerging 
technologies will help manufacture and 
distribute its products more efficiently. 
Some of these technologies will enable  it 
to build quality into its manufacturing 
processes, while others will enhance its 
throughput or facilitate collaboration to 
realize economies of scale. (See Figure 3) 
 
Research Approach  
To provide a helicopter view and the 
updated analysis of the pharmaceutical 
cold chain in emerging economics, 
narrative literature review would be the 
main approach to structure this research, 
and China was selected to be the case 
study. The research steps include 
performing a preliminary search of the 
literatures, glancing over the contents of 
selected materials to refine the questions 
need to be explored, synthesizing the 
contents, and making conclusion. The final 
output of the review analysis would be the 
results of analysis, the overview of 
pharmaceutical cold chain in China and the 
challenges/opportunities of pharmaceutical 
cold chain in China.
 
Figure 3: By 2020, the healthcare supply chains would be fully integrated  
Source: PwC (2011)
Issues of pharmaceutical cold chain  
A well-developed cold chain systems 
ensure that adequate amounts of 
pharmaceuticals, mostly biologics 
medicine like vaccine, can be procured, 
stored, and distributed in a manner that 
minimizes waste, avoids stock outs and 
maintains proper temperature control to 
prevent damage. The issues of 
pharmaceutical cold chain nowadays 
include: 
 Regulation: Pharmaceutical industry 
is highly regulated by law globally. 
Certainly, pharmaceutical supply 
chain has various global regulatory 
requirements, such as Good Storage 
and Distribution Practices, to meet 
while handling, storing, and 
distributing environmentally sensitive 
products. 
 Network of pharmaceutical cold chain 
transport logistics: Pharmaceuticals 
cold chain logistics is a series of 
whole refrigerated scheme, special 
logistics network and supply chain 
system to maintain the quality of 
pharmaceuticals by keeping the 
constant state of low temperature 
from production to consumption 
process. 
 New technology: Innovation is 
leading to better insulation products, 
the ability to maintain a specific 
temperature range for longer time 
periods and in-transit monitoring that 
doesn't require the package to be 
opened, thereby lessening the risk of 
counterfeiting and diversion. The 
innovations are highly in need in cold 
chain, such as phase-change materials 
(PCMs), insulating materials, 
environmental data loggers, software 
for monitoring and tracking shipment 
conditions, three-dimensional 
modeling software to optimize 
package design, integration of 
temperature protection/monitoring by 
logistics providers and temperature-
controlled bulk containers to protect 
larger shipments. 
 Prevent cold chain break: Cold chain 
breaks can, and do, happen at any 
time. Preventing the cold chain break 
has been one of the important issues 
in pharmaceutical cold chain 
management. To improve this 
situation, more management system 
and technology such as cumulative 
heat monitoring devices should be 
implemented to cold chain 
management system 
 China’s pharmaceutical market 
 The healthcare reform programme 
triggered the market demand. China is 
going to be the second large 
pharmaceutical market by sales in the 
world, but the status is arguably due 
to  the size of its population, as the 
market is not yet mature. The 
combined forces of economic and 
demographic development, 
government stimulus, enhanced health 
awareness among the public, market 
consolidation, and improving R&D 
capability may help the country to 
grow into a more sophisticated market 
within the next decade. Key drivers of 
market expansion are the rising health 
care awareness and needs fueled by 
economic growth, large and aging 
population, increasing total and per 
capita heath spending, and the 
ongoing healthcare reform and 12th 
Five-Year Plan supportive measures. 
According to BMI, the China’s 
pharmaceutical market sales could 
reach 132 billion USD in 2017 with 9 
% annual growth rate. 
 Biologics has been targeted as a key 
development sector by Chinese 
government. Although biologics only 
account for 10 percent of the total 
pharmaceuticals market in China, 
their recent annual growth rate of 32.2 
percent has been quite impressive. 
The Five-Year Plan provisions 
specifically related to biotechnology 
applications in the life sciences 
industry are expected to take effect 
shortly. It has been reported that 
China's government will invest 
RMB10 billion to support major new 
drug innovation, with RMB5–10 
million in funding  for each project 
on average from 2011 through 2015. 
The investment on biologics will also 
rigger the demand of cold chain 
service. 
 The major issue to China’s 
pharmaceutical industry: building a 
more efficient ecosystem, from 
regulation authority to supply chain, 
from dispersed industry structure to 
integrated value chain. In China, the 
pharmaceutical distribution system is 
too dispersive, large amount of 
distributor levels made the end price 
unstable and the end price was 
stacked up as well. To relieve the pain 
of high pharmaceutical product end 
price, Chinese government has 
released policy to refine the 
pharmaceutical procurement process 
of public hospitals (more than 80% of 
hospitals in China are government 
owned) and to restructure the 
pharmaceutical distribution system. 
Figure 4: Chinese pharmaceutical industry value chain 
Source: Deloitt (2011)
China’s pharmaceuticals distribution 
system  
 China’s drug distribution environment 
is fragment and complex. China’s 
pharmaceutical distribution base is 
extremely fragmented. Before 2009, 
there are more than 13,000 
distributors, most providing access to 
only a local market or even just one or 
two hospitals. The fierce competition 
has led to widespread discounting. As 
a result, many distributors are 
lossmaking. Many newly established 
distributors are reported to be 
unregistered, and it has been a critical 
safety issue in pharmaceutical supply 
chain 
 Consolidation and integration is the 
top priority. To fixed the high drug 
price and inefficient distribution 
system, China's Ministry of 
Commerce (MOFCOM) has outlined 
its plans for the development of the 
pharmaceutical sector from 2011 to 
2015, focusing on the distribution of 
drugs 
 
New regulation-GSP, will restore the 
cold chain management  
On January 22, 2013, the newly revised 
Good Supply Practice (GSP) for 
Pharmaceutical Products was adopted at 
the executive meeting of the China’s 
Ministry of Health and officially issued, 
and has been formally implemented on 
June 1, 2013. The new GSP revision 
constitutes a major adjustment of China’s 
policy for supervision of drug distribution, 
which greatly raised the threshold of 
qualification requirements and standards 
for engaging in drug distribution practice. 
To enhance the cold chain guidelines, on 
October 23, 2013, CFDA issued five GSP 
appendices (2013 No. 38) as GSP 
supporting documents, including the 
Management of storage and transportation 
for drugs needed to be retriggered or 
frozen, Management of Computer systems 
for drug suppliers, Management of 
Automatic temperature and humidity 
monitoring, Drug delivery and 
acceptance/Validation management. The 
new guideline will help the cold chain 
industry to develop a higher qualified 
ecosystem and may generate new business 
opportunities such as 3PL (third-party 
logistics provider) in the future. 
 
Biologics medicine: the driving force of 
pharmaceutical cold chain  
The dramatic shift in pharmaceutical 
industry from small molecule drugs to high 
value biologics drugs is not only happing 
in US and Europe market but also in 
China, even with higher growth tare, 
increasing the need to focus on cold chain 
management. 
 
Conclusion 
 Consistent with the 12th FYP for 
drug safety, the new GSP reflects 
government efforts on improving 
drug quality by raising standards for 
the whole healthcare industry, which 
could accelerate industry 
consolidation. After implementing 
the new GSP in June 2013, the 
government declared 5 cold-chain 
relevant guidelines under new GSP 
close behind, pushing process of 
industry restricting. The impact 
would be the same for big or small 
distributors, but big distributors can 
more easily assume the costs for 
compliance with the regulations, 
while small companies are much less 
flexible. Since all the service 
providers need to follow the new 
regulation by the end of 2016, more 
M&A activities will happen and 
more qualified cold chain service 
providers should appear in the near 
future. 
 Before implementing new GSP, most 
of the big pharmaceutical companies 
build up their own cold chain 
facilities, including storage and 
logistics, to ensure the quality and 
safety and prevent the product from 
degrading caused by break-up cold 
chain. However, the model is not 
economics efficient and not easy to 
optimize the operation. In the near 
future, the status may not change too 
much, and the cold chain logistic will 
still rely on the pharmaceutical 
companies’ self-built logistics center. 
However, the high quality 
pharmaceutical cold chain system 
would steadily set up under the new 
regulations, and the current 
ecosystem should change in the mid-
term, such as more integrated cold 
chain, new supply model and 3 PL 
service. 
 Although the new GSP has made the 
regulation on cold chain 
management, however the 
operational standards and best 
practice still need to be clarified and 
set up. By the end of 2013, the China 
Association of Pharmaceutical 
Commerce united Sinopharm Group 
Co, Jointoown Pharmaceutical group, 
China Resources Pharmaceutical 
Group Limited and Harbin 
Pharmaceutical Group Co., etc., nine 
major pharmaceutical cold chain 
distribution enterprises to establish 
drug distribution security laboratory. 
The main mission of the lab is to 
formulate the standard and best 
practice which align with key players 
and government. Thus, the practical 
standards of cold chain management 
may be well set up in the couple 
years. 
 Due to the healthcare reforms, 12th 
5-YP and the increasing aging 
population, the demand of biologics 
could keep steep growing in the near 
future, but the current poorly 
structured cold chain system may 
force the pharmaceutical company to 
invest more on cold chain 
management. Besides the promising 
market may attract more service 
provider to join this market, 
including foreign players, the 
ecosystem of pharmaceutical cold 
chain will dynamically change to 
adapt the fast changing market 
demand and regulations. 
 
Key takeaways  
Under the fast changing industry 
environment, many new challenges are 
waiting to be explored. According to the 
literatures review result in this research, 
some opportunities ahead can be pointed 
out include: 
 3PL will play a role in China’s 
pharmaceutical cold chain in long-
term. The current cold chain logistic 
is mostly self-build by big 
pharmaceutical company because it’s 
hard to find a trustable and qualified 
3PL currently, therefore the 
pharmaceutical enterprises can only 
build up their own infrastructure even 
the cost is extreme high. However, 
once the new regulation completely 
implemented in the future and also the 
industry standards are practiced well, 
3PL could be an solution to the 
industry, not only for big 
pharmaceutical companies but small 
and medium enterprises. 
 In the near future, new technology 
and equipment will be highly in need 
to build a modern cold chain system. 
The new GSP requires IT-based 
management and automatic 
monitoring of storage temperature and 
humidity, and introduced new 
management philosophies and 
methods for quality risk management, 
system internal evaluation and 
equipment validation. Regarding 
infrastructure, the newly revised GSP 
calls for the comprehensive 
implementation of IT-based 
management and specified 
requirements on the facilities, 
network environment, database and 
functions of applied software; 
required retail and wholesale 
enterprises to adopt automatic 
temperature and humidity monitoring 
system for drug warehouse to conduct 
continuous and effective real-time 
monitoring of warehouse 
environment; and provide special 
facilities and equipment for the 
storage and transportation of drugs 
stored in a refrigerator or freezer. The 
China’s future pharmaceutical cold 
chain will need more technology 
solutions to complete a modern cold 
chain.  
 To align with the national healthcare 
reforms- ensue the people safe and 
affordable pharmaceutical, a new 
business model highly link with 
government could be an opportunity. 
For instance, a 3PL contracts with 
government to deliver specific 
products set with high quality cold 
chain management to regional 
hospitals.  
  
Figure 6: Roadmap of China’s Pharmaceutical Cold Chain 
Source: Author (2014) 
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